Ask Lazlo

life sciences… only

Severin Schwan: Roche Pharmaceuticals, CEO

80xName: Severin Schwan

Company: Roche Pharmaceuticals

Position: CEO

Bio (from Business Week)

Severin Schwan has been Group Chief Executive Officer of Roche Diagnostics Corporation since January 1, 2008. Dr. Schwan serves as Chief Executive Officer of Roche Holding AG. He served as Chief Executive Officer of Roche Diagnostics Corporation a Diagnostics Divisions of Roche Holding Ag, since January 1, 2006. He served as Trainee of Corporate Finance, Roche Basel from 1993 to 1995, Head Finance & Administration, Roche Brussels from 1995 to 1998, Head Finance & Informatics of Roche Grenzach and Member of the Executive Board of Roche Deutschland Holding GmbH from 1998 to 2000, Head Global Finance & Services of Roche Diagnostics from 2000 to 2004, Head Region Asia Pacific of Roche Diagnostics from 2004 to 2006. He served as a Head of Diagnostics Asia-Pacific of Roche Holding Ag from 2004 to January 1, 2006. He served as Head of Global Finance & Services for the Diagnostics Division from 2000 until 2004. Dr. Schwan holds Degree in Economics at University of Innsbruck, University of York and University of Oxford Mag. rer.soc.oec. (Innsbruck, 1991) and Law at University of Innsbruck Mag. iur. (Innsbruck, 1991) and Doctorate in Law at University of Innsbruck Research studies at University Louvain, Belgium Dr. iur. (Innsbruck, 1993).


WSJ Interview (Dec. 8, 2008)


November 28, 2008 Posted by | Profiles | , , | Leave a comment

Robert Nelsen: ARCH Venture Partners, Managing Director

Robert NelsenCompany: Arch Venture Partners

Position: Co-founder and Managing Director

Bio (from

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.

Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including Sapphire Energy, Ikaria, Illumina (ILMN), Adolor (ADLR), Aviron (AVIR, acquired by Medimmune-MEDI), Caliper Life Sciences (CALP), Trubion Pharmaceuticals (TRBN), Array BioPharma (ARRY), NetBot, deCODE Genetics (DCGN), Nanosys, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), GenVec (GNVC), R2 Technology (acquired by Hologic-HOLX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Spaltudaq, VLST, Ensemble Discovery, Accelerator, Apoptos, Fate Therapeutics, Agios Pharmaceuticals, and Everyday Learning.

Mr. Nelsen is a director of Ikaria, Sapphire Energy, Fate Therapeutics, Agios Pharmaceuticals, NeurogesX, and Kythera Biopharmaceuticals. He previously serves on the boards of Trubion Pharmaceuticals, Surface Logix, Adolor, NetBot, Everyday Learning, Spaltudaq, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and, among others. He also serves as a director of the Fred Hutchinson Cancer Research Institute. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.

November 28, 2008 Posted by | Profiles, Venture Capital | , , , , | Leave a comment

Chris Viehbacher: Sanofi-Aventis, CEO

Chris ViehbacherDivisional President/Director

GlaxoSmithKline PLC

Brentford, Middlesex ,  EN

Sector: HEALTHCARE  /  Drug Manufacturers – Major

Officer since January 2003
Bio (from
47 Years Old
Christopher Viehbacher, Appointed on 31st January 2008. President, US Pharmaceuticals. Mr Viehbacher joined the Group in 1988 and has held a variety of senior positions in Europe and Canada. He was appointed President, US Pharmaceuticals in January 2003. He served on the European Commission approved G10 working group to restore the competitiveness of the EU Pharmaceutical industry. He is a board member of PhRMA, the CEO Roundtable on Cancer and Research!America.

November 25, 2008 Posted by | Pharma, Profiles | Leave a comment

Richard Clark: Merck, CEO

Richard ClarkCEO/President/Director/Chairman of the Board

Merck & Company, Incorporated

Whitehouse Station ,  NJ

Sector: HEALTHCARE  /  Drug Manufacturers – Major

Officer since January 2000
61 Years Old
Richard T. Clark, Chairman of the Board (since April 2007), President and Chief Executive Officer (since May 2005), President, Merck Manufacturing Division (June 2003-May 2005) of the Company; Chairman, President (January 2000-December 2002) and Chief Executive Officer (January 2003-June 2003), Medco Health Solutions, Inc., formerly a wholly owned subsidiary of the Company Director, Project HOPE and United Negro College Fund; Chairman, Federal Health Care Legislation Committee of Pharmaceutical Research and Manufacturers of America; Trustee, Washington & Jefferson College and The Conference Board.

November 23, 2008 Posted by | Pharma, Profiles | , | Leave a comment

Christoph Westphal: Sirtris, CEO


Christoph WestphalChristoph Westphal, M.D., Ph.D., co-founded Sirtris in 2004 and has since served as Chief Executive Officer.  Under his leadership, Sirtris has become a recognized pioneer in the research and development of small molecule drugs that target the sirtuins, a family of enzymes that control the aging process.

In 2007, Dr. Westphal successfully led the company through its initial public offering, resulting in recognition by the Boston Globe as one of the Globe 100 top IPOs of 2007.  In June 2008, GSK acquired Sirtris for $720 million, and Dr. Westphal continues to lead Sirtris as an independent discovery performance unit within GSK.

Prior to establishing Sirtris, Dr. Westphal co-founded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) and Acceleron as CEO.  Dr. Westphal was formerly a general partner at a venture fund and a consultant with McKinsey.  He earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University.  He graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University.

Dr. Westphal currently serves on the Board of Directors for Alnara Pharmaceuticals, Concert Pharmaceuticals and Magen BioSciences, and he serves on the Board of Fellows of Harvard Medical School.  Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals including CellNature and Nature Genetics.

Dr. Westphal has received a number of industry awards, including the 2008 Outstanding Individual of the Year Award at the annual Laguna Biotech Meeting; recognition in the Pharmaceutical Executive “45 Under 45” andPharmaVOICE 100 issues, both in 2008; Mass High Tech All Star Award in 2007; and Ernst & Young’s New England Entrepreneur of the Year award in the Biopharmaceutical category in 2006.

Dr. Westphal enjoys traveling (he has visited over 130 countries) and playing the cello.  He is also fluent in English, German, Spanish and French.  Dr. Westphal is married with three young children.

November 21, 2008 Posted by | Biotech, Pharma, Profiles | , , , , | Leave a comment